Clinical Trial Update: Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin mesylate in hormone-refractory/metastatic prostate cancer. The study is completed and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-23